Form 4: STAAR Surgical Director Arthur Butcher Receives Annual Equity Compensation

STAAR Surgical Co. Director Arthur C. Butcher was granted 5,341 Restricted Stock Units and 9,708 Common Stock Options as part of the company's annual non-employee director equity compensation program.

Summary

• Arthur C. Butcher, a Director of STAAR Surgical Co. (STAA), received equity awards on June 18, 2025.
• The awards consist of 5,341 Restricted Stock Units (RSUs) and 9,708 Common Stock Options.
• Each RSU represents the right to receive one share of the Corporation's common stock upon vesting.
• The Common Stock Options have an exercise price of $16.85 per share.
• Both the RSUs and options vest in full on the earlier of June 18, 2026, or the Corporation's 2026 Annual Meeting of Shareholders.
• The options are exercisable from June 18, 2026, and expire on June 17, 2035.
• These awards are part of the Corporation's annual non-employee director equity compensation program for the 2025-2026 term.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as the filing indicates a routine and expected compensation event for a director, which aligns their interests with shareholders. It does not contain any negative surprises or significant new information beyond the compensation details.

Positives

• The grant of equity awards aligns the interests of Director Arthur C. Butcher with those of the shareholders, as his compensation is tied to the company's stock performance.
• The awards are part of a routine, established compensation program, indicating stable corporate governance practices regarding director remuneration.

Future Outlook

The equity awards granted to Director Arthur C. Butcher are scheduled to vest in full on the earlier of June 18, 2026, or the Corporation's 2026 Annual Meeting of Shareholders, with options exercisable from the vesting date until June 17, 2035.

Management Comments

• The equity awards granted to the Reporting Person on June 18, 2025, are pursuant to the Corporation's annual non-employee director equity compensation program for the 2025-2026 term.

Industry Context

The granting of equity awards to non-employee directors is a common practice across various industries, including the medical device sector, to attract and retain qualified board members and align their financial interests with long-term shareholder value.

Corporate Governance

Related Party Transactions

• The transaction involves the grant of equity awards to Arthur C. Butcher, a Director of STAAR Surgical Co., which is a related party transaction conducted under the company's established annual non-employee director equity compensation program.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial incentives with shareholder interests, potentially encouraging decisions that enhance long-term stock value.
• Employees: No direct impact on employees is indicated by this specific filing.

Next Steps

• Vesting of 5,341 Restricted Stock Units on the earlier of June 18, 2026, or the 2026 Annual Meeting of Shareholders.
• Vesting and exercisability of 9,708 Common Stock Options on the earlier of June 18, 2026, or the 2026 Annual Meeting of Shareholders.

Key Dates

Keywords

STAAR Surgical, STAA, SEC Form 4, Equity Compensation, Director Compensation, Restricted Stock Units, Stock Options, Insider Transaction, Corporate Governance